12/27
08:02 am
ikt
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Low
Report
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
12/26
08:02 am
ikt
Inhibikase Therapeutics (NYSE:IKT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
High
Report
Inhibikase Therapeutics (NYSE:IKT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
12/13
07:50 am
ikt
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Medium
Report
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
12/11
09:55 am
ikt
Rating for IKT
Report
Rating for IKT
12/11
08:43 am
ikt
Inhibikase Therapeutics (NYSE:IKT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $4.00 price target on the stock.
Medium
Report
Inhibikase Therapeutics (NYSE:IKT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $4.00 price target on the stock.
12/11
07:57 am
ikt
Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald
Medium
Report
Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald